Abnormal EGFR overexpression and signaling are associated with malignant tumors of the lung (Hirsch et al., 2009), pancreas (Lemoine et al., 1992; Ueda et al., 2004), brain (Hicks et al., 2006), bladder (Chow et al., 1997; Hashmi et al., 2018), breast (Wang et al., 2017), prostate (Peraldo-Neia et al., 2011), and other cancers (Mendelsohn and Baselga, 2000; Ciardiello and Tortora, 2008). Here, EGFR is linked to cancer.